Tavapadon, a drug being tested to treat early Parkinson's disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week. Parkinson’s disease ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Luckily for AbbVie, Cerevel quickly redeemed itself. Tavapadon, a potential first-in-class Parkinson's disease treatment it was developing, met its primary endpoint in the phase 3 Tempo-2 trial.